Abstract Details

Title Investigating Cerebral Sinus Venous Thrombosis after COVID-19 Vaccination in Adults

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 13-006

Background CSVT has been reported after COVID-19 infections.

Objective To investigate whether there is an association between Cerebral Sinus Venous Thrombosis (CSVT) and COVID-19 vaccination.

Design/Methods

Data from the Vaccine Adverse Event Reporting System (VAERS) was used. The reporting rate of CSVT cases after COVID-19 vaccination was compared to the reporting rate of CSVT after all other vaccinations in 3 time periods: the vaccine period (December 2020-July 2021), the pre-vaccine period (April 2020-November 2020) and the pre-COVID-19 period (January 2019-August 2019). Self-controlled case series and case-centered analysis were used. Six weeks after vaccination was defined as the risk period of probable association.

Results 217 cases with CSVT after COVID-19 vaccination were reported during COVID-19 vaccination period. The reporting rate of CSVT after COVID-19 vaccination was 1.12 per million vaccination, which is in the range of incidence within the general population. No cases of CSVT were reported after all other vaccinations in the vaccine period, pre-vaccine period and pre-COVID-19 period. Using self-controlled and case centered analyses, there was a significant difference in the reporting rate of CSVT after COVID vaccination between the risk and control period (88.9% vs 1.8-6.0% p<0.0001). The reporting rate of CSVT for each vaccine used in USA was significantly higher with Johnson & Johnson compared to Pfizer and Moderna vaccines (2.75 vs 1.3 vs 0.8 <0.0001). All reporting rates did not exceed the incidence of CSVT in the general population.

Conclusions There is no association between CSVT and COVID-19 vaccination. Although the reporting rate of CSVT after COVID-19 was significantly higher during the risk period compared to control period, it was within the expected incidence range in general population. In addition, cases of CSVT triggered by unreported or undiagnosed infection and inflammation cannot be excluded. Controlled studies are needed to assess the relationship between CSVT and COVID-19 vaccination.

Authors/Disclosures
Kazim Jaffry PRESENTER	Mr. Jaffry has nothing to disclose.
Kranthi K. Mandava	Mr. Mandava has nothing to disclose.
Mustafa Jaffry	Mr. Jaffry has nothing to disclose.
	No disclosure on file
	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received publishing royalties from a publication relating to health care.